Published • loading... • Updated
Korlym improves results for diabetes patients taking GLP-1 drugs
Summary by Cushing's Disease News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Korlym improves results for diabetes patients taking GLP-1 drugs
Treatment with Korlym (mifepristone) may help lower blood sugar and promote weight loss in people with hard-to-control diabetes and high cortisol levels who are also taking medications targeting GLP-1, according to a new analysis of data from dozens of patients in the CATALYST clinical trial. Corcept Therapeutics, the company that sells Korlym, presented the new analyses at the American Diabetes Association’s 86th Scientific Sessions, held June …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
